Abstract:OBJECTIVE:To identify potential prognosis related clinical and molecular factors in malignant pleural mesothelioma (MPM).METHODS:Seventy-nine patients with MPM treated in Beijing Cancer Hospital from June 1996 to May 2012 were enrolled in this study. Clinical and pathological data were collected, including age, gender, smoking status, treatment, response, and molecular biomarkers such as thymidylate synthetase (TS) expression, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) gene rearrangement. The primary endpoint was overall survival (OS). SPSS 16.0 statistical analysis software was used for univariate analysis. The expression of TS was detected by immunohistochemistry (IHC). Fluorescence in situ hybridization (FISH) was performed to detect EML4-ALK gene rearrangement. Efficacy of the chemotherapy regimen including pemetrexed was analyzed with these molecular biomarkers.RESULTS:The median survival time (MST) of all patients was 15.5 months (95% CI: 10.6 - 20.4). Univariate survival analysis revealed that treatment factors including receiving operation, systemic chemotherapy, pemetrexed-based chemotherapy and capability of receiving second (or above) line chemotherapy were significantly related with OS. The MST of patients receiving operation was 5.4 months (95% CI: 3.6 - 7.3), significantly shorter than the 17.7months (95% CI: 11.8 - 23.5) in those who didn't receive operation (P = 0.030). Patients receiving systemic chemotherapy had a longer MST of 18.0 months (95% CI: 12.3 - 23.8) as compared to the 7.9 months (95% CI: 1.1 - 14.7) in those who didn't (P = 0.001). The MST of pemetrexed-based chemotherapy was 21.9 months (95% CI: 14.1-29.7) compared with 8.8 months (95% CI: 4.2 - 13.4) of regimens without pemetrexed (P = 0.000). For patients capable of receiving second (or above) line chemotherapy the MST was longer (21.0 months, 95% CI: 12.7 - 29.3) than those who could not (12.1 month, 95% CI: 6.4 - 17.8 month), P = 0.022. For the 42 patients treated with pemetrexed-based chemotherapy, the objective response rate (ORR) was 33.3% (14/42), the disease control rate (DCR) was 78.6% (33/42), the median progression-free survival (PFS) was 4.8 months (95% CI: 3.6 - 6.0) and MST was 21.9 months (95% CI: 14.1 - 29.7). Twenty-nine patients provided adequate specimens for detection of TS expression and 6 cases (20.7%) were positive. EML4-ALK gene rearrangement was studied in 32 patients and 6 (18.8%) were positive. TS expression was found to be inversely related to PFS of pemetrexed-based chemotherapy (P = 0.041). The MST was 19.6 months (95% CI: 6.0 - 7.9) in EML4-ALK-positive patients and 9.57 months (95% CI: 2.7 - 4.3) in negative ones (P = 0.159).CONCLUSIONS:Systemic chemotherapy especially pemetrexed-based regimen was proved to be a superior option for MPM with a significantly prolonged OS. Correlation between TS expression or EML4-ALK rearrangement and outcome of pemetrexed-based chemotherapy for MPM may contribute to future individualized treatment, which needs further validation from large-scale prospective studies.

The Value of COX-2, NF-κB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma

Prognostic Value of Neutrophil-to-lymphocyte Ratio in Melanoma

Prognostic significance of inflammation-related and electrolyte laboratory variables in patients with malignant pleural mesothelioma

The Prognostic Impact of Neutrophil to Lymphocyte Ratio in Patients with Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors.

Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma

Biomarkers to predict the benefits of immune‐checkpoint blockade‐based therapy in patients with malignant peritoneal mesothelioma (Review)

Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma

Impact of preoperative inflammatory and nutritional markers on the prognosis of patients with peritoneal metastasis of colorectal cancer

C-Myb and Its Effector COX-2 As an Indicator Associated with Prognosis and Therapeutic Outcome in Colorectal Cancer

Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment

Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study

[Prognostic value of combining preoperative serum tumor markers and peripheral blood routine indexes in patients with colorectal cancer].

[Prognosis Related Clinical and Molecular Factors in Malignant Pleural Mesothelioma].

Survival prediction in peritoneal mesothelioma: a nomogram based on SEER data and a Chinese cohort

Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei

Analysis of Correlation between Blood Inflammation Indicators in Peripheral Blood and Prognosis of Patients with Multiple Myeloma

Prognostic value of matrix metalloproteinase-2 protein and matrix metalloproteinase-9 protein in colorectal cancer: a meta-analysis

CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness

Expression of C-MET, COX-2, MSS and Ki-67 in colorectal cancer and its correlation with the prognosis

Increased MPO in Colorectal Cancer is Associated with High Peripheral Neutrophil Counts and a Poor Prognosis: A TCGA with Propensity Score-Matched Analysis

Diagnostic and Prognostic Values of Endothelial-Cell-Specific Molecule-1 with Malignant Pleural Effusions in Patients with Non-Small Cell Lung Cancer